177 related articles for article (PubMed ID: 34145795)
21. Genomic Profiling Identifies Association of
Zhu GG; Nafa K; Agaram N; Zehir A; Benayed R; Sadowska J; Borsu L; Kelly C; Tap WD; Fabbri N; Athanasian E; Boland PJ; Healey JH; Berger MF; Ladanyi M; Hameed M
Clin Cancer Res; 2020 Jan; 26(2):419-427. PubMed ID: 31615936
[TBL] [Abstract][Full Text] [Related]
22. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
Lachowiez CA; Reville PK; Kantarjian H; Jabbour E; Borthakur G; Daver N; Issa G; Furudate K; Tanaka T; Pierce S; Tang G; Patel KP; Medeiros J; Abbas HA; Haddad F; Hammond D; Short NJ; Maiti A; Yilmaz M; Sasaki K; Takahashi K; Pemmaraju N; Konopleva M; Garcia-Manero G; Ravandi F; Kadia TM; Loghavi S; DiNardo CD
Am J Hematol; 2022 Nov; 97(11):1443-1452. PubMed ID: 36054614
[TBL] [Abstract][Full Text] [Related]
23. Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations.
Toth LN; de Abreu FB; Tafe LJ
Hum Pathol; 2018 Aug; 78():138-143. PubMed ID: 29723602
[TBL] [Abstract][Full Text] [Related]
24. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
25. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Borger DR; Tanabe KK; Fan KC; Lopez HU; Fantin VR; Straley KS; Schenkein DP; Hezel AF; Ancukiewicz M; Liebman HM; Kwak EL; Clark JW; Ryan DP; Deshpande V; Dias-Santagata D; Ellisen LW; Zhu AX; Iafrate AJ
Oncologist; 2012; 17(1):72-9. PubMed ID: 22180306
[TBL] [Abstract][Full Text] [Related]
26. IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes.
Wang N; Wang F; Shan N; Sui X; Xu H
Acta Haematol; 2017; 138(3):143-151. PubMed ID: 28873367
[TBL] [Abstract][Full Text] [Related]
27. Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Kato Kaneko M; Liu X; Oki H; Ogasawara S; Nakamura T; Saidoh N; Tsujimoto Y; Matsuyama Y; Uruno A; Sugawara M; Tsuchiya T; Yamakawa M; Yamamoto M; Takagi M; Kato Y
Cancer Sci; 2014 Jun; 105(6):744-8. PubMed ID: 24898068
[TBL] [Abstract][Full Text] [Related]
28. IDH mutations in cancer and progress toward development of targeted therapeutics.
Dang L; Yen K; Attar EC
Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
[TBL] [Abstract][Full Text] [Related]
29. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.
Bill M; Jentzsch M; Bischof L; Kohlschmidt J; Grimm J; Schmalbrock LK; Backhaus D; Brauer D; Goldmann K; Franke GN; Vucinic V; Niederwieser D; Mims AS; Platzbecker U; Eisfeld AK; Schwind S
Blood Adv; 2023 Feb; 7(3):436-444. PubMed ID: 35381077
[TBL] [Abstract][Full Text] [Related]
30. Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Platt MY; Fathi AT; Borger DR; Brunner AM; Hasserjian RP; Balaj L; Lum A; Yip S; Dias-Santagata D; Zheng Z; Le LP; Graubert TA; Iafrate AJ; Nardi V
J Mol Diagn; 2015 Nov; 17(6):661-8. PubMed ID: 26331834
[TBL] [Abstract][Full Text] [Related]
31. A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma.
Catteau A; Girardi H; Monville F; Poggionovo C; Carpentier S; Frayssinet V; Voss J; Jenkins R; Boisselier B; Mokhtari K; Sanson M; Peyro-Saint-Paul H; Giannini C
Acta Neuropathol Commun; 2014 Jun; 2():58. PubMed ID: 24889502
[TBL] [Abstract][Full Text] [Related]
32. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
[TBL] [Abstract][Full Text] [Related]
33. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
Zhang C; Moore LM; Li X; Yung WK; Zhang W
Neuro Oncol; 2013 Sep; 15(9):1114-26. PubMed ID: 23877318
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups.
Damm F; Thol F; Hollink I; Zimmermann M; Reinhardt K; van den Heuvel-Eibrink MM; Zwaan CM; de Haas V; Creutzig U; Klusmann JH; Krauter J; Heuser M; Ganser A; Reinhardt D; Thiede C
Leukemia; 2011 Nov; 25(11):1704-10. PubMed ID: 21647152
[TBL] [Abstract][Full Text] [Related]
35. IDH1 and IDH2 mutations in gliomas.
Yan H; Parsons DW; Jin G; McLendon R; Rasheed BA; Yuan W; Kos I; Batinic-Haberle I; Jones S; Riggins GJ; Friedman H; Friedman A; Reardon D; Herndon J; Kinzler KW; Velculescu VE; Vogelstein B; Bigner DD
N Engl J Med; 2009 Feb; 360(8):765-73. PubMed ID: 19228619
[TBL] [Abstract][Full Text] [Related]
36. [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].
Liu QQ; Yin XX; Zou Y; Yu TP; Gong J; Chen XQ; Nie L; Xu M; Zhang MN; Zhou Q; Chen N
Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):658-663. PubMed ID: 30220117
[No Abstract] [Full Text] [Related]
37. Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.
Jin J; Hu C; Yu M; Chen F; Ye L; Yin X; Zhuang Z; Tong H
PLoS One; 2014; 9(6):e100206. PubMed ID: 24936872
[TBL] [Abstract][Full Text] [Related]
38. IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.
Zou Y; Zeng Y; Zhang DF; Zou SH; Cheng YF; Yao YG
Biochem Biophys Res Commun; 2010 Nov; 402(2):378-83. PubMed ID: 20946881
[TBL] [Abstract][Full Text] [Related]
39. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Chen EC; Li S; Eisfeld AK; Luskin MR; Mims A; Jones D; Antin JH; Cutler CS; Koreth J; Ho VT; Gooptu M; Romee R; El-Jawahri A; McAfee SL; DeFilipp Z; Soiffer RJ; Chen YB; Fathi AT
Transplant Cell Ther; 2021 Jun; 27(6):479.e1-479.e7. PubMed ID: 33840625
[TBL] [Abstract][Full Text] [Related]
40. IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas.
Qi ST; Yu L; Lu YT; Ou YH; Li ZY; Wu LX; Yao F
Oncol Rep; 2011 Dec; 26(6):1479-85. PubMed ID: 21874255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
